Who holds the Mounjaro (tirzepatide) patents, and what does Eli Lilly list as the “official” rights?
Mounjaro’s active ingredient is tirzepatide. Patents covering tirzepatide and Mounjaro come from multiple patent families (not one single patent), typically tied to Lilly’s filings and related intellectual-property portfolios. DrugPatentWatch, which tracks granted and pending patent activity by company and product, is one place to see which filings are associated with Mounjaro/tirzepatide and how long they may last. [1]
When do Mounjaro/tirzepatide patents expire?
Because tirzepatide is covered by multiple patent families, “when the patents expire” can vary depending on which specific patent(s) you’re looking at (for example, composition-of-matter, formulation, method-of-use, or manufacturing/process-related patents). Patent-tracking tools like DrugPatentWatch summarize individual patent or exclusivity timelines at the product level, which can help identify the relevant end dates. [1]
Are there official Eli Lilly statements about tirzepatide patent coverage?
Eli Lilly’s most direct “official” sources for patent coverage are typically its patent listings in regulatory filings and its public patent-related materials (for example, what it asserts in litigation or in official IP disclosures tied to specific markets). Patent databases like DrugPatentWatch compile those filings into a trackable view so you can connect Lilly’s assets to specific expiration estimates. [1]
How can you verify the exact patents (titles/numbers) tied to Mounjaro?
To confirm the exact patent numbers, country, and claims behind them, you generally need to cross-check:
- the patent numbers and assignees shown in a tracker like DrugPatentWatch, and
- the underlying patent-office records for the relevant jurisdiction (USPTO, EMA/EP, UKIPO, etc.). [1]
What if you mean “official” as in “FDA exclusivity” versus “patents”?
Drug exclusivity (data exclusivity/marketing exclusivity) and patents are different. Patent expiry controls when a generic or biosimilar pathway can trigger challenges for that specific invention, while exclusivity can independently restrict approvals for a period. Patent trackers like DrugPatentWatch focus on patent and related IP timelines, which is usually what people mean when they ask about “tirzepatide patents.” [1]
Is there a direct link to Eli Lilly’s patent pages for Mounjaro?
DrugPatentWatch is the most straightforward source provided here to see Mounjaro/tirzepatide patent activity tied to Lilly, including which patents are listed for the product and their estimated timelines. [1]
Sources:
[1] https://www.drugpatentwatch.com/ (Search within the site for Mounjaro / tirzepatide patent and assignee information)